BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21220493)

  • 1. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.
    Lu X; Wei W; Fenton J; Nahorski MS; Rabai E; Reiman A; Seabra L; Nagy Z; Latif F; Maher ER
    Mol Cancer Ther; 2011 Jan; 10(1):80-9. PubMed ID: 21220493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).
    Lu X; Boora U; Seabra L; Rabai EM; Fenton J; Reiman A; Nagy Z; Maher ER
    Oncogene; 2014 Feb; 33(8):956-65. PubMed ID: 23416984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
    Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.
    Hudon V; Sabourin S; Dydensborg AB; Kottis V; Ghazi A; Paquet M; Crosby K; Pomerleau V; Uetani N; Pause A
    J Med Genet; 2010 Mar; 47(3):182-9. PubMed ID: 19843504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folliculin deficient renal cancer cells show higher radiosensitivity through autophagic cell death.
    Zhang Q; Si S; Schoen S; Jin XB; Chen J; Wu G
    J Urol; 2014 Jun; 191(6):1880-8. PubMed ID: 24434776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt-Hogg-Dubé syndrome.
    Furuya M; Hasumi H; Baba M; Tanaka R; Iribe Y; Onishi T; Nagashima Y; Nakatani Y; Isono Y; Yao M
    Lab Invest; 2017 Mar; 97(3):343-351. PubMed ID: 27991910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.
    Hong SB; Oh H; Valera VA; Stull J; Ngo DT; Baba M; Merino MJ; Linehan WM; Schmidt LS
    Mol Cancer; 2010 Jun; 9():160. PubMed ID: 20573232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies.
    Schmidt LS
    Fam Cancer; 2013 Sep; 12(3):357-64. PubMed ID: 23108783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility.
    Preston RS; Philp A; Claessens T; Gijezen L; Dydensborg AB; Dunlop EA; Harper KT; Brinkhuizen T; Menko FH; Davies DM; Land SC; Pause A; Baar K; van Steensel MA; Tee AR
    Oncogene; 2011 Mar; 30(10):1159-73. PubMed ID: 21057536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
    Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
    Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?
    Johannesma PC; Houweling AC; Menko FH; van de Beek I; Reinhard R; Gille JJ; van Waesberghe JT; Thunnissen E; Starink TM; Postmus PE; van Moorselaar RJ
    Fam Cancer; 2016 Apr; 15(2):297-300. PubMed ID: 26603437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.
    Chen J; Futami K; Petillo D; Peng J; Wang P; Knol J; Li Y; Khoo SK; Huang D; Qian CN; Zhao P; Dykema K; Zhang R; Cao B; Yang XJ; Furge K; Williams BO; Teh BT
    PLoS One; 2008; 3(10):e3581. PubMed ID: 18974783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
    Zhang Q; Xu Y; Zhang Z; Li J; Xia Q; Chen Y
    Gene; 2021 Feb; 769():145243. PubMed ID: 33069804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion.
    Schneider M; Dinkelborg K; Xiao X; Chan-Smutko G; Hruska K; Huang D; Sagar P; Harisinghani M; Iliopoulos O
    Fam Cancer; 2018 Jan; 17(1):135-139. PubMed ID: 28623476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer.
    Bartram MP; Mishra T; Reintjes N; Fabretti F; Gharbi H; Adam AC; Göbel H; Franke M; Schermer B; Haneder S; Benzing T; Beck BB; Müller RU
    BMC Med Genet; 2017 May; 18(1):53. PubMed ID: 28499369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein.
    Takagi Y; Kobayashi T; Shiono M; Wang L; Piao X; Sun G; Zhang D; Abe M; Hagiwara Y; Takahashi K; Hino O
    Oncogene; 2008 Sep; 27(40):5339-47. PubMed ID: 18663353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
    Hasumi H; Baba M; Hasumi Y; Furuya M; Yao M
    Int J Urol; 2016 Mar; 23(3):204-10. PubMed ID: 26608100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
    Näf E; Laubscher D; Hopfer H; Streit M; Matyas G
    Fam Cancer; 2016 Jan; 15(1):127-32. PubMed ID: 26342594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical characterization of renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Iribe Y; Kuroda N; Nagashima Y; Yao M; Tanaka R; Gotoda H; Kawakami F; Imamura Y; Nakamura Y; Ando M; Araki A; Matsushima J; Nakatani Y; Furuya M
    Pathol Int; 2015 Mar; 65(3):126-32. PubMed ID: 25597876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
    Baba M; Furihata M; Hong SB; Tessarollo L; Haines DC; Southon E; Patel V; Igarashi P; Alvord WG; Leighty R; Yao M; Bernardo M; Ileva L; Choyke P; Warren MB; Zbar B; Linehan WM; Schmidt LS
    J Natl Cancer Inst; 2008 Jan; 100(2):140-54. PubMed ID: 18182616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.